Curative Effect Observation Of Improving Atheroscleroscierosis In Type2Diabetic Patients With Early Inflammatory Factor With Quyidi Capsule

Objective To observe the clinical efficacy of Quyidi capsule on T2DM with early intervention, and explore the possible mechanism of improving AS cured T2DM.Method a randomized, controlled study,90cases of T2DM patients with early diabetic AS were randomly, divided into the treatment group and control group,45cases each group. Control group:conventional treatment+Tangmaikang granule(one bag,3times a day). Treatment group:conventional treatment+Quyidi capsule(5pills each time,2times a day). Two groups of patients were treated for24weeks,observation of IL-6, TNF-α, hsCRP, TCM syndrome scores, carotid IMT, FPG, PPG, HbAlc, TC, TG, HDL-C, LDL-C.Results1. Compared with before treatment, the two groups of TCM syndromes were significanly different(P<0.01); compared with the control group, the treatment group scores had significant differences(P<0.01), success rate had significant differences(P<0.01), total effective rate had obvious difference(P<0.05).2. Compared with before treatment, two groups FPG,PPG, HbAlc were obvious differences(P<0.05); compared with control group after treatment, the treatment group FPG, PPG,HbAlc had significantly different (P<0.01).3. Two groups LDL-C, HDL-C, TG, TC after treatment were obviously different (P<0.05); compared with the control group after treatment,treatment group LDL-C, TG, TC decreased significantly (P<0.01),HDL-C has no obvious differences (P>0.05).4. The carotid IMT changes in two groups were not obviously different(P>0.05), the two groups IMT had no obvious changes (P>0.05)after treatment.5. Compared with that before treatment, there were no significant differences between two groups IL-6(P>0.05), treatment group TNF-α, hsCRP had significant differences (P<0.01), control group TNF-α had obvious differences (P<0.05), control group hsCRP had no significant differences (P>0.05); compared with control group after treatment,treatment group TNF-α had obvious differences (P<0.05).Conclusion1. Quyidi capsule can significantly improve the clinical symptoms of early AS in T2DM patients.2. Quyidi capsule can effectively downregulate FPG, PPG, HbAlc, TC, TG, LDL,upregulate HDL-C, and the curative effect was better than Tangmaikang granule.3. Quyidi capsule reduced hsCRP, TNF-α, restrained the inflammatory elevation of IL-6further, effectively relieved inflammation in T2DM, may be the mechanism of controlling AS.